Novartis recall of generic Zantac expands to US

British drugmaker GlaxoSmithKline, meanwhile, said it would halt distribution of Zantac product in countries where it sells the heartburn drug.

By Kristin Jensen • Sept. 26, 2019

GSK to spend $120M on new manufacturing hub for drug pipeline

The investment is part of nearly $400 million the British pharma has spent since 2017 to build out its vaccine and specialty drug production in the U.S.

By Kristin Jensen • Sept. 26, 2019

Novartis stops distributing generic Zantac as carcinogen concerns rise

While the FDA continues to investigate NDMA contamination in generic Zantac, Canadian regulators moved to halt distribution of the heartburn drug.

By Kristin Jensen • Sept. 19, 2019

Private equity firm to buy Sanofi's oldest plant in India

Advent International snagged Sanofi's generics unit for $2 billion last year. Now, that unit is ready to acquire the Indian plant for about $37 million.

By Kristin Jensen • Sept. 12, 2019

Mallinckrodt selling CDMO business for up to $250M

The deal gives needed cash to Mallinckrodt, which is under pressure for its role in the opioid epidemic, and provides another example of private equity's interest in contract manufacturing.

By Kristin Jensen • Sept. 12, 2019

Latest Civica Rx pact aims to ease shortage of emergency medicine

The Intermountain-led coalition of providers inked a deal with Exela for supplying sodium bicarbonate to member hospitals.

By Samantha Liss • Sept. 10, 2019

How to get upstream right the first time while accelerating the time from DNA to material?

BioReliance's mini-pool approach enables efficient selection of high producing cell lines and accelerates upstream processes.

Sept. 6, 2019

Celltrion taps Lonza to produce some of its Remicade biosimilar

Under the deal, Lonza will make Remsima drug substance at its commercial facility in Singapore to cover European and North American markets.

By Jacob Bell • Sept. 5, 2019

Novo Nordisk Foundation makes green grant to Danish-US university collaboration

The $27 million grant will fund a five-year program in biopharmaceutical manufacturing, run in partnership by NC State and the Technical University of Denmark.

By Jonathan Gardner • Sept. 5, 2019

Catalent's legacy business outshined by acquisitions

The recent additions of Cook Pharmica, Juniper and Paragon are driving more revenue growth than the contract manufacturer's base business. 

By Jacob Bell • Aug. 29, 2019

Biopharma jobs boom in Massachusetts, though challenges still exist

Many more jobs have opened up in R&D than in manufacturing, which saw growth of just 1% between 2017 and 2018.

By Jacob Bell • Aug. 27, 2019

HHS to fund further manufacturing of Merck Ebola vaccine

An outbreak of the virus in the Democratic Republic of the Congo is now the second largest on record, making vaccination programs more critical.

By Ned Pagliarulo • Aug. 22, 2019

As supply shortages persist, ADMA relaunches immune globulin drug

Three of the plasma-derived therapies are currently in shortage, according to the FDA, putting pressure on hospitals and infusion centers.

By Ned Pagliarulo • Aug. 22, 2019

Pfizer injects $500M more into gene therapy manufacturing

The money is going toward a North Carolina plant that will make the inactivated viruses used to deliver gene therapies and employ 300 staff.

By Jacob Bell • Aug. 21, 2019

Technology permeates the cold chain warehouse — but has its limits

At DHL's cold storage facility in Chicago, technologies such as RFID are designed to withstand cold temperatures and help monitor shipments, including those for life sciences companies.

By Jen A. Miller • Aug. 13, 2019

Nektar battered over manufacturing issues and Bristol-Myers pullback

A study of skin, kidney and bladder cancer found disease progressed faster after patients received inactive doses of a Nektar drug paired with Opdivo.

By Jonathan Gardner • Aug. 9, 2019

PE firm to buy Cambrex for $2.4B amid flurry of CDMO acquisitions

Permira’s planned deal marks the third in the space topping $1 billion this year.

By Kristin Jensen • Aug. 7, 2019

Novo buys North Carolina plant from Purdue

Located near Novo's sprawling Clayton site, Purdue's facility gives the buyer capacity to manufacture oral drugs like its experimental version of semaglutide.

By Ned Pagliarulo • Aug. 6, 2019

Regenxbio inks viral vector rights deal with Pfizer

Pfizer gains non-exclusive rights to AAV9 vector technology from Regenxbio, a collaboration that supports one of the pharma's early gene therapy programs.

By Kristin Jensen • Aug. 1, 2019

Akorn takes $74 million charge to settle shareholder lawsuit

Investors accused the generics maker of knowingly ignoring data integrity issues at the company's manufacturing facilities — problems that eventually derailed a $4.3 billion deal with Fresenius. 

By Ned Pagliarulo • Updated Aug. 1, 2019

Pfizer may send EpiPen manufacturing to generics spinoff

The drug giant is in talks to transfer its troubled Meridian Medical Technologies unit to the merged business with Mylan.

By Kristin Jensen • Aug. 1, 2019

White House backs importing drugs from abroad

The Trump administration's latest drug price plan features ideas Republicans traditionally oppose and breaks with past claims about the FDA's ability to safely oversee importation.

By Jonathan Gardner • July 31, 2019

Lonza plans facility expansion amid pharma focus

While profit dipped over the first half of 2019, Lonza predicts strong sales growth driven by its pharma and biotech-facing unit.

By Kristin Jensen • July 25, 2019

Nonprofit US generics company secures supplier in Hikma

The hospital-created group Civica Rx signed a deal for production of 14 sterile injectables, aiming to alleviate drug shortages.

By Jonathan Gardner • July 23, 2019

Biohaven blames Apotex for FDA rejection of ALS drug

Biohaven said it is working with the FDA to solve the manufacturing-related problems that led to a Complete Response Letter for the experimental drug. 

By Andrew Dunn • July 22, 2019